Myelofibrosis in patients with chronic myeloid leukemia treated with interferon-alpha

Trepanobiopsies of the bone marrow were studied in 46 patients in a chronic phase of chronic myeloid leukemia in different periods after the beginning of interferon-alpha therapy. Progression of myelofibrosis was observed in 2 cases only. Regression of myelofibrosis was observed in 14 cases of 29 (3...

Full description

Saved in:
Bibliographic Details
Published inArkhiv patologii Vol. 65; no. 4; p. 9
Main Authors Kumas Sotiris, Semenova, E A, Turkina, A G, Zakharova, A V, Domracheva, E V, Khoroshko, N D, Frank, G A
Format Journal Article
LanguageRussian
Published Russia (Federation) 01.07.2003
Subjects
Adolescent
Adult
Antineoplastic Agents - therapeutic use
Bone Marrow - drug effects
Bone Marrow - pathology
Female
Humans
Interferon-alpha - therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
Male
Middle Aged
Primary Myelofibrosis - drug therapy
Primary Myelofibrosis - etiology
Primary Myelofibrosis - pathology
Prognosis
Online AccessGet more information

Cover

More Information
Summary:Trepanobiopsies of the bone marrow were studied in 46 patients in a chronic phase of chronic myeloid leukemia in different periods after the beginning of interferon-alpha therapy. Progression of myelofibrosis was observed in 2 cases only. Regression of myelofibrosis was observed in 14 cases of 29 (34.2%). A negative correlation between reticulin myelofibrosis and response to therapy was found. Disappearance of diffuse reticulin myelofibrosis in all cases was followed by a cytogenetic response.
ISSN:0004-1955